6th TCR-based Therapies Summit
The 6th TCR-based Therapies Summit returns as the only forum created solely for TCR experts pioneering best-in-class cell- and biologic-based approaches, to dive into T-cell receptor biology and navigate the specific challenges faced as this community strives to drive discovery efforts through to clinical success.
View the brand-new 2025 agenda
Join forces with teams across discovery, translation, R&D, and clinical development to analyze clinical data, validate novel targets, boost TCR discovery and optimization, and reinvent durability in the solid TME to expand treatment potential to new HLA, more indications and even beyond oncology, while driving clinical efficacy and safety.
Take a peek at the leading experts sharing exclusive learnings in April:
- *New Data Annelise Vuidepot, Chief Technology Officer, Immunocore
- Andrea Mayer-Mokler, Vice President & Global Head, Clinical Sciences, Immatics
- *New Data Cagan Gurer, Senior Vice President, Discovery & Preclinical Development, TScan Therapeutics
- Rachel Abbott, Chief Executive Officer, Pan Cancer T
- *New Data Zhen Su, Chief Executive Officer, Marengo Therapeutics
- *New Data Gary Shapiro, Vice President, Discovery Biology, Affini-T Therapeutics
- *New Data Claudia Ouyang, Senior Director, Cell & Gene Therapies, BioNTech
- Jordan Jarjour, Chief Scientific Officer, Moonlight Bio
View the full list of 25+ industry-leading speakers
With the majority of talks sharing new data and novel insights, don’t let your team get left behind. Join us in April to collaborate with this specific community to transform your TCR therapies and pipeline strategy to deliver best-in-class TCR therapies for solid tumors and beyond.
Quick links: Website | Event Guide | Registration
